Rob C van Wijk\*1,2, Marjorie Z Imperial\*1,2, Radojka M Savic1,2, Belén P Solans#1,2

<sup>1</sup>University of California San Francisco Schools of Pharmacy and Medicine, San Francisco, California, USA <sup>2</sup>UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, CA, United States of America

\*The authors contributed equally to this work, #Corresponding author: <a href="mailto:belen.perezsolans@ucsf.edu">belen.perezsolans@ucsf.edu</a>

**Supplementary Material 1: Checklist for reporting an IPDMA.** \*Relative to the research question of interest, different plots might apply, showing examples if the research question of interest is dosing evaluation BOL = Below quantification limit; GOFs – Goodness of fit plots; LOO = Limit of quantification; VPC = Visual predictive check.

Search	Research question of interest
	Report the research question and rationale
	Process used to identify relevant studies
	Mention databases searched, search queries, and predefined criteria
	Number of authors/sponsors/data sharing platforms initially approached for data
	Consider including a CONSORT-type flow diagram
	Number of authors/sponsors that did not provide data and reasons why
	Discuss briefly possible impacts on results and conclusions
	Number of authors/sponsors/data sharing platforms who provided data and if the whole set was provided or not
	Cite platforms and publications for transparency
General	Patient characteristics, overall and by study
	Report these results for the reader to understand similarities and differences between study populations
	Study characteristics, specific technical details (sampling, timing of sampling, LOQ, etc)
	Report these results for the reader to understand similarities and differences between study technical aspects
	Missing data and how that is handled
	Discuss methods of handling missing data, possible implications for bias, and how to mitigate
	Detailed report of the modelling and statistical analysis
	Specify a reproducible step-wise analysis plan for full transparency
Visual Exploration	Overall available data
	Visualize data included in the analysis on all relevant dimensions (e.g. concentration over time, BQL over time)
	Available data by stratifications of interest (studies, relevant covariates)
	Demonstrate similarities or differences in observations by strata of interest (at least per study, also e.g. by sex or age)
Model Diagnostics	Overall VPC
	Show appropriate model across full data, with prediction-corrected VPC in case of large concentration ranges
	VPC per study
	Show appropriate model per study, discuss possible misfits per study including implications
	VPC per covariate of interest
	Stratify VPC by dose in case of different doses, also e.g. by sex or age
	Overall GOFs  Show appropriate model garage full data, consider less transforming PRED/IRRED us ORS in case of large consentration ranges.
	Show appropriate model across full data, consider log-transforming PRED/IPRED vs OBS in case of large concentration ranges
	GOFs highlighting studies/per study
	Show appropriate model per study, discuss possible misfits per study including implications
	Overall residual plots
	Show appropriate model across full data
	Residual plots per study
	Show appropriate model per study, discuss possible misfits per study including implications
Main Findings*	Overall exposure evaluation
	Report model-predicted exposure, compare to possible target, discuss similarities or differences with original studies
	Exposure evaluation per covariate of interest
	Discuss similarities or differences in model-predicted exposure per covariate of interest including implications for dosing
	New dosing recommendations
	Propose new dosing recommendation(s) justified by model-predicted exposure, covariates, and targets
	Proportion of patients achieving target thresholds in different dosing recommendations
	Report proportion achieving targets so the reader can compare dosing strategies